
In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.
Dr. Ikuo Hirano and Profs. Arjan Bredenoord and Ingrid Terreehorst highlight the benefits of interdisciplinary care in EoE.

In this clip from the April WCPD 2025 symposium, Dr Amy Paller highlights CCL17 (TARC) as an important biomarker in AD.

In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).

This cross-TA plenary session addressed challenges in type 2 inflammation-driven diseases. Esteemed faculty, including Profs Klaus Rabe, Sharon Dell, Anju Peters, Milli Gupta, Eric Simpson, Stella Lee, and moderator Oscar Palomares, discussed strategies to enhance quality of life, reduce disease burden, and prioritize patient-centered care.
Prof. Salvatore Oliva discusses the latest clinical data for EoE that included patients from childhood to adulthood.

September 25th marks this year’s observance and celebration of World Lung Day!

Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.
Dr. Dhandapani Ashok highlights treatment options for patients with EoE aged 12 years and younger and the importance of shared decision-making.

The ADVENT program will present a symposium to discuss diagnosis, pathophysiology, comorbidities of atopic dermatitis in children, as well as emerging treatment options for management of atopic dermatitis (AD) in children, who are candidates for systemic therapy at the 2024 European Academy of Paediatric Societies (EAPS) Congress.